EUCTR2017-001103-77-GB
Active, not recruiting
Phase 1
A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above - INVICTUS
Vaccitech Limited0 sites862 target enrollmentMay 15, 2018
ConditionsInfluenzaMedDRA version: 20.0 Level: LLT Classification code 10016790 Term: Flu System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
DrugsVaxigrip Tetra TM
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Influenza
- Sponsor
- Vaccitech Limited
- Enrollment
- 862
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Volunteer is willing and has capacity to provide written informed consent for participation in the trial (in the Investigator’s opinion).
- •\-Male or female adults, aged 65 years and above
- •\-Able and willing (in the Investigator’s opinion) to comply with all study requirements
- •\-Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner
- •\-Eligible to receive seasonal influenza vaccine
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range 0
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •\-Any history of anaphylaxis in reaction to vaccination, history of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. egg allergy).
- •\-Ongoing terminal illness with a life expectancy estimated to be approximately \<6 months.
- •\-Continuous use of oral anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)
- •\-Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study
- •\-Participation in another clinical trial of an investigational medicinal product in the 30 days preceding enrolment, or planned use during the study period
- •\-Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data
- •\- Receipt of annual seasonal influenza vaccine prior to enrolment (for the same influenza season volunteers are recruited in)
- •\-Not willing to comply with study procedures
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab plus Lenalidomide in Patients with Relapsed or Refractory Follicular LymphomaFollicular lymphomaMedDRA version: 19.0Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-002467-42-FRF. Hoffmann-La Roche Ltd38
Active, not recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Diffuse large B-cell LymphomaFollicular Lymphoma (FL) or Diffuse Large B-cell Lymphoma (DLBCL)MedDRA version: 20.0Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-004845-25-DEF. Hoffmann-La Roche Ltd.36
Active, not recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Diffuse large B-cell LymphomaEUCTR2015-004845-25-PLF. Hoffmann-La Roche Ltd36
Active, not recruiting
Phase 1
A Study of MPDL3280A plus Obinutuzumab and Bendamustine or Obinutuzumab and CHOP in Patients with Follicular Lymphoma or DiffuseLarge B-Cell LymphomaFollicular lymphoma or diffuse large B-cell lymphomaMedDRA version: 20.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001364-19-ITF. HOFFMANN - LA ROCHE LTD.91
Active, not recruiting
Phase 1
Study of a combination therapy in patients with Waldenstrom Macroglobulinemia and active disease not previously treatedEUCTR2013-002388-25-ITAzienda Ospedaliera Ospedali Riuniti Marche Nord40